Seeking Alpha

Big Pharma firms, NIH to join up to study major diseases

  • Ten major pharmaceuticals companies are getting together with the National Institutes of Health and other organizations in a five-year partnership that will look to understand the science behind Alzheimer's, Type 2 diabetes, rheumatoid arthritis and lupus.
  • In an unusual move, the normally secretive participants will share scientists, tissue, blood samples and data, with the aim being to identify targets for new drugs.
  • The firms involved include Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), GlaxoSmithKline (GSK), Takeda (TKPHF) and Sanofi (SNY).
  • Those that haven't joined include Amgen (AMGN), Roche (RHHBY) and AstraZeneca (AZN).
From other sites
Comments (4)
  • theo_rhetoric
    , contributor
    Comments (217) | Send Message
     
    Collaboration has produced some of the greatest leaps in solutions. This is the kind of leadership I desire from my government.
    4 Feb 2014, 08:45 AM Reply Like
  • RWMostow
    , contributor
    Comments (1558) | Send Message
     
    I do not see cancer on the list. What happened?

     

    -rwm
    4 Feb 2014, 09:07 AM Reply Like
  • jameswparker
    , contributor
    Comments (13) | Send Message
     
    No major progress has been made in the treatment of these 4 diseases. Sharing & collaboration could move the pharmaceutical companies forward by decades in less than 5 yrs.
    4 Feb 2014, 11:16 AM Reply Like
  • BlueOkie
    , contributor
    Comments (7448) | Send Message
     
    Since when has the gov't got involved in something besides defense and improved upon it. If they find a cure, who develops the drug? You still have FDA. What exactly does NIH bring to the party.
    4 Feb 2014, 12:21 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs